Jan 7, 2026 | Main Page Post, Rejuvenair, SPRAY-CB
SPRAY-CB met its primary endpoint and multiple secondary endpoints with statistical significance, FDA review underway BOSTON, Jan. 7, 2026 /PRNewswire/ — CSA Medical, Inc., a medical device company focused on interventional pulmonary therapies, today...
Oct 8, 2024 | Main Page Post, Product News, Rejuvenair, SPRAY-CB
Underlying proof of rejuvenative healing indicative of airway remodeling corresponds with clinical efficacy and improved quality of life Boston, MA—Oct 8, 2024: /PRNewswire/ — CSA Medical, Inc., a leader in developing spray cryotherapy solutions for the...
Sep 16, 2024 | Main Page Post, Product News, Rejuvenair
Research reveals rejuvenative changes in cellular populations indicative of airway remodeling correspond with clinical efficacy and improved quality of life BOSTON, Sept. 16, 2024 /PRNewswire/ –CSA Medical, Inc., today announced multiple presentations at the...
Sep 9, 2024 | Main Page Post, Product News, Rejuvenair
TVM Capital Life Science and Yonjin Venture co-led the round, joined by a strong syndicate of existing investors BOSTON, Sept. 9, 2024 /PRNewswire/ — CSA Medical Inc., developer of The RejuvenAir® System, a Breakthrough Medical Device advancing the power of...
Feb 7, 2024 | Main Page Post, Rejuvenair, SPRAY-CB
The RejuvenAir System is a minimally invasive medical device therapy which aims to target the underlying cause of COPD with Chronic Bronchitis BOSTON, Feb. 7, 2024 /PRNewswire/ — CSA Medical Inc., a developer of medical devices advancing the power of liquid...
Sep 6, 2022 | Main Page Post, Rejuvenair
Metered Cryospray treats damaged airways enabling a rejuvenative healing response BOSTON, Sept. 6, 2022 /PRNewswire/ — CSA Medical, Inc., today announced results from the first randomized, controlled study of Metered Cryospray (MCS) utilizing the RejuvenAir®...
